Diagnosis, Progress, and Treatment Update of Kawasaki Disease
International Journal of Molecular Sciences · 11.09.2023 · 24 (18) · 13948
DOI: 10.3390/ijms241813948 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.09.2023. Verfasst von Ho-Chang Kuo. Beteiligte Einrichtung: Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, MicroRNAs, COVID-19. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Ministry of Science and Technology of Taiwan.
Abstract (Originalsprache)
Kawasaki disease (KD) is an acute inflammatory disorder that primarily affects children and can lead to coronary artery lesions (CAL) if not diagnosed and treated promptly. The original clinical criteria for diagnosing KD were reported by Dr. Tomisaku Kawasaki in 1967 and have been used for decades. However, research since then has highlighted the limitations of relying solely on these criteria, as they might lead to underdiagnosis or delayed diagnosis, potentially increasing the risk of coronary artery complications. This review appears to discuss several important aspects related to KD diagnosis and management. The current diagnostic methods for KD might need updates, especially considering cases that do not fit the typical clinical criteria. Recognizing diagnostic pitfalls and distinguishing KD from other conditions that might have similar clinical presentations is essential. The differences and similarities between KD and Multisystem Inflammatory Syndrome in Children (MIS-C), another inflammatory condition that has been associated with COVID-19, were also reviewed. The review explores the potential role of eosinophil count, new biomarkers, microRNA panels, and scoring systems in aiding the diagnosis of KD. Overall, the review article provides a comprehensive overview of the evolving landscape of KD diagnosis and management, incorporating new diagnostic methods, biomarkers, and treatment approaches to improve patient outcomes and reduce the risk of complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
- Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
- Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
- Taiwan Association for the Promotion of Molecular Hydrogen, Kaohsiung 83301, Taiwan.
ORCID-Profile: Ho-Chang Kuo
Förderung
- Kaohsiung Chang Gung Memorial Hospital
- Chang Gung Memorial Hospital
- Ministry of Science and Technology of Taiwan
Zitieren
APA
Kuo, H. C. (2023). Diagnosis, Progress, and Treatment Update of Kawasaki Disease. International Journal of Molecular Sciences, 24(18), 13948. https://doi.org/10.3390/ijms241813948
Vancouver
Kuo HC. Diagnosis, Progress, and Treatment Update of Kawasaki Disease. International Journal of Molecular Sciences. 2023;24(18):13948. doi:10.3390/ijms241813948
BibTeX
@article{Kuo2023,
author = {Kuo, Ho-Chang},
title = {Diagnosis, Progress, and Treatment Update of Kawasaki Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {18},
pages = {13948},
doi = {10.3390/ijms241813948}
}
EUVIMED